We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Novo Nordisk will increase its diabetes sales force by 700 in an attempt to strengthen its hold on the U.S. insulin market, the firm announced. Read More
Pharmaceutical researchers at the University of Maryland are set to evaluate how well drugmakers respond to and process adverse event reports during manufacturing, according to a grant announcement from the School of Pharmacy’s Center on Drugs and Public Policy. Read More
Pfizer’s sudden decision to end its clinical trials for torcetrapib, a once-likely successor to its blockbuster cholesterol drug Lipitor, not only harms its financial outlook, but also opens the door for other companies to take control of that market, analysts say. Read More
More than 800 stores in 11 additional states are set to offer consumers 30-day supplies of generic prescription drugs for $4 due
to another round of expansions to the Wal-Mart program. Read More
Generic drugmakers successfully capitalizing on the multi-billion dollar antihypertensive market are driving large brand producers to redirect their research and development strategies toward a more profitable market, a new Datamonitor report reveals.
Read More
More than 800 stores in 11 additional states are set to offer consumers 30-day supplies of generic prescription drugs for $4 due to another round of expansions to the Wal-Mart program. Read More
The average cost of developing a new therapeutic biotechnology product is more than $1.2 billion, including the costs of drugs that fail in testing and the time associated with bringing these products to market, according to a new study by the Tufts Center for the Study of Drug Development. Read More
A day after Eon Labs launched its 25-mg generic version of AstraZeneca’s Toprol-XL Nov. 21, the brand manufacturer announced entry of its own authorized generic version of metoprolol succinate in an agreement with generic producer, Par Pharmaceuticals. Read More
A recent study shows that angioplasty using stents -- also known as percutaneous coronary intervention (PCI) -- may offer no significant benefit compared with standard drug therapy in treating some heart attack patients.